Explore the words cloud of the ART-AI project. It provides you a very rough idea of what is the project "ART-AI" about.
The following table provides information about the project.
|Coordinator Country||France [FR]|
|Total cost||3˙539˙583 €|
|EC max contribution||2˙477˙708 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-11-01 to 2021-10-31|
Take a look of project's partnership.
Current radiotherapy is fully reliant on semi-automatic treatment planning systems (TPS) that depend on highly toxic CT scans and human clinical expertise for creating a treatment plan. As a result, the procedure is inefficient and inefficacious resulting in poor treatment outcome and severe side effects. In recent years, there has been an emergence of the concept of MRI-guided radiotherapy, wherein non-toxic and high resolution MRI images are used to guide treatment planning. As a result, several key players in the radiotherapy market such as Elekta and ViewRay have introduced MRI embedded linear acclerators to perform MRI imaging during radiotherapy administration. However, as of yet no TPS exists on the market that enables fully automated MRI-guided radiotherapy, in order to provide real-time dose adjustment.
To meet this market gap, TheraPanacea, a young start-up working on cutting edge AI technology, aims to introduce the world's first fully automated TPS for MRI guided radiotherapy - the ART-AI platform. This platform is built using state-of-the-art technology in reinforcement learning and employs proprietary Monte Carlo algorithms to perform anatomical simulation using MRI images to rapidly update the treatment plan on-the-fly. Moreover, the platform employs latest advances in positioning algorithms via a deformable registration framework to ensure automatic and precise patient position adjustment inside the linear accelerator. Thus, the ART-AI platform has the potential to revolutionize radiotherapy and enable it to achieve its full potential.
In this SME-2 project, we will finalize the development steps of the platform, incoporate all the software modules into one suite and perform clinical validation in collaboration with our clinical partners. The end-result of this SME-2 project will be a fully validated software platform ready for commercial launch.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ART-AI" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ART-AI" are provided by the European Opendata Portal: CORDIS opendata.
MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINERead More
Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbingRead More
CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.Read More